E Fund Management Co. Ltd. Purchases 1,130 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

E Fund Management Co. Ltd. increased its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 22.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,203 shares of the company’s stock after buying an additional 1,130 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Vera Therapeutics were worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. KBC Group NV lifted its position in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after buying an additional 1,387 shares during the last quarter. Arizona State Retirement System lifted its position in Vera Therapeutics by 22.9% in the 4th quarter. Arizona State Retirement System now owns 12,586 shares of the company’s stock worth $532,000 after buying an additional 2,348 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Vera Therapeutics by 27.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company’s stock worth $568,000 after buying an additional 2,882 shares during the last quarter. Point72 DIFC Ltd increased its stake in Vera Therapeutics by 8.4% in the 3rd quarter. Point72 DIFC Ltd now owns 43,789 shares of the company’s stock worth $1,935,000 after purchasing an additional 3,376 shares during the period. Finally, Victory Capital Management Inc. increased its stake in Vera Therapeutics by 13.5% in the 3rd quarter. Victory Capital Management Inc. now owns 38,253 shares of the company’s stock worth $1,691,000 after purchasing an additional 4,546 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Price Performance

VERA opened at $28.82 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a 52-week low of $25.99 and a 52-week high of $51.61. The stock has a market capitalization of $1.82 billion, a PE ratio of -11.04 and a beta of 1.17. The stock’s 50 day moving average price is $34.45 and its 200-day moving average price is $40.00.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.11. On average, equities research analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00. Following the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at $3,701,521.94. The trade was a 16.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 52,500 shares of company stock worth $2,305,625 over the last ninety days. 21.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the company. JPMorgan Chase & Co. decreased their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. Wolfe Research assumed coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target on the stock. Guggenheim lifted their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Wells Fargo & Company assumed coverage on Vera Therapeutics in a research note on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price target on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Vera Therapeutics has a consensus rating of “Buy” and an average price target of $64.67.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.